[US-헬스케어] 09/10 Wall St. Recap
LLYBULL As a senior equity analyst, I evaluate Eli Lilly and Co. (LLY) based on its strategic moves in the obesity and biopharmaceutical sectors. Despite a recent minor stock pullback (-3.57%), the company’s expansion of its oral weight-loss pill into…